Neumora Therapeutics appoints Joshua Pinto as CEO and Doron Sagman as CMO ahead of IND filing

Neumora Therapeutics announced leadership changes, naming Joshua Pinto, Ph.D., as its new chief executive officer.

Pinto, who joined Neumora in 2021 as chief financial officer and most recently served as president, will replace co‑founder Paul Berns, who moves to executive chair of the board.

The company also appointed Doron Sagman, M.D., as chief medical officer; Sagman previously held senior roles at Eli Lilly Canada and Mind Cure Health.

The appointments come as Neumora prepares to file an IND application and start a Phase 1 trial of its NLRP3 inhibitor for obesity, and as it expects data readouts from its Phase 1 Alzheimer’s and schizophrenia programs.